09.05.2022 • News

LyondellBasell Wins China PE Contracts

LyondellBasell has won contracts to provide its Lupotech PE technology to two separate Chinese companies. The value of the contracts was not disclosed.

For Jiangsu Hongjing New Material, LyondellBasell will provide its process technology for two 200,000 t/y LDPE/ethylene vinyl acetate lines to be built in Lianyungang, Jiangsu province. These will be the fourth and fifth polyolefin lines for the company that are based on LyondellBasell’s technology.

“Demand for both EVA and LDPE remains strong in the current dynamic market. In particular, higher value applications such as for solar panel lamination and encapsulant are in strong demand, driven mainly by the ongoing energy transition,” said Neil Nadalin, director global licensing and services at LyondellBasell.

The second deal is with Zhejiang Petroleum & Chemical (ZPC), which will use LyondellBasell’s process for a 100,000 t/y autoclave line and a 300,000 t/y tubular line, producing mostly EVA copolymers. A 400,000 t/y tubular line producing LDPE homopolymers will also be included in the project at Zhoushan City, Zhejiang province.

Nadalin said in the near future ZPC will produce a total of more than 2.7 million t/y polyolefins based on LyondellBasell’s process technology.

Start-up dates for the new EVA/PE plants were not disclosed.

Author: Elaine Burridge, Freelance Journalist

© LyondellBasell Industries Holdings B.V. 2022
© LyondellBasell Industries Holdings B.V. 2022

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read